PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCER

Robert Hromas, Elizabeth Williamson, Suk-Hee Lee, Jac Nickoloff

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Approximately half of all cancers harbor chromosomal translocations that can either contribute to their origin or govern their subsequent behavior. Chromosomal translocations by definition can only occur when there are two DNA double-strand breaks (DSBs) on distinct chromosomes that are repaired heterologously. Thus, chromosomal translocations are by their very nature problems of DNA DSB repair. Such DNA DSBs can be from internal or external sources. Internal sources of DNA DSBs that can lead to translocations can occur are inappropriate immune receptor gene maturation during V(D)J recombination or heavy-chain switching. Other internal DNA DSBs can come from aberrant DNA structures, or are generated at collapsed and reversed replication forks. External sources of DNA DSBs that can generate chromosomal translocations are ionizing radiation and cancer chemotherapy. There are several known nuclear and chromatin properties that enhance translocations over homologous chromosome DSB repair. The proximity of the region of the heterologous chromosomes to each other increases translocation rates. Histone methylation events at the DSB also influence translocation frequencies. There are four DNA DSB repair pathways, but it appears that only one, alternative non-homologous end-joining (a-NHEJ) can mediate chromosomal translocations. The rate-limiting, initial step of a-NHEJ is the binding of poly-adenosine diphosphate ribose polymerase 1 (PARP1) to the DSB. In our investigation of methods for preventing oncogenic translocations, we discovered that PARP1 was required for translocations. Significantly, the clinically approved PARP1 inhibitors can block the formation of chromosomal translocations, raising the possibility for the first time that secondary oncogenic translocations can be reduced in high risk patients.

Original languageEnglish (US)
Pages (from-to)176-195
Number of pages20
JournalTransactions of the American Clinical and Climatological Association
Volume127
StatePublished - Jan 1 2016

Fingerprint

Genetic Translocation
Double-Stranded DNA Breaks
Poly Adenosine Diphosphate Ribose
Neoplasms
Chromosomes
V(D)J Recombination
Ionizing Radiation
Histones
Methylation
Chromatin
Drug Therapy
DNA
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCER. / Hromas, Robert; Williamson, Elizabeth; Lee, Suk-Hee; Nickoloff, Jac.

In: Transactions of the American Clinical and Climatological Association, Vol. 127, 01.01.2016, p. 176-195.

Research output: Contribution to journalArticle

Hromas, Robert ; Williamson, Elizabeth ; Lee, Suk-Hee ; Nickoloff, Jac. / PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCER. In: Transactions of the American Clinical and Climatological Association. 2016 ; Vol. 127. pp. 176-195.
@article{a47faad744274fb48ea636697cc542a4,
title = "PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCER",
abstract = "Approximately half of all cancers harbor chromosomal translocations that can either contribute to their origin or govern their subsequent behavior. Chromosomal translocations by definition can only occur when there are two DNA double-strand breaks (DSBs) on distinct chromosomes that are repaired heterologously. Thus, chromosomal translocations are by their very nature problems of DNA DSB repair. Such DNA DSBs can be from internal or external sources. Internal sources of DNA DSBs that can lead to translocations can occur are inappropriate immune receptor gene maturation during V(D)J recombination or heavy-chain switching. Other internal DNA DSBs can come from aberrant DNA structures, or are generated at collapsed and reversed replication forks. External sources of DNA DSBs that can generate chromosomal translocations are ionizing radiation and cancer chemotherapy. There are several known nuclear and chromatin properties that enhance translocations over homologous chromosome DSB repair. The proximity of the region of the heterologous chromosomes to each other increases translocation rates. Histone methylation events at the DSB also influence translocation frequencies. There are four DNA DSB repair pathways, but it appears that only one, alternative non-homologous end-joining (a-NHEJ) can mediate chromosomal translocations. The rate-limiting, initial step of a-NHEJ is the binding of poly-adenosine diphosphate ribose polymerase 1 (PARP1) to the DSB. In our investigation of methods for preventing oncogenic translocations, we discovered that PARP1 was required for translocations. Significantly, the clinically approved PARP1 inhibitors can block the formation of chromosomal translocations, raising the possibility for the first time that secondary oncogenic translocations can be reduced in high risk patients.",
author = "Robert Hromas and Elizabeth Williamson and Suk-Hee Lee and Jac Nickoloff",
year = "2016",
month = "1",
day = "1",
language = "English (US)",
volume = "127",
pages = "176--195",
journal = "Transactions of the American Clinical and Climatological Association",
issn = "0065-7778",
publisher = "American Clinical And Climatological Association",

}

TY - JOUR

T1 - PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCER

AU - Hromas, Robert

AU - Williamson, Elizabeth

AU - Lee, Suk-Hee

AU - Nickoloff, Jac

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Approximately half of all cancers harbor chromosomal translocations that can either contribute to their origin or govern their subsequent behavior. Chromosomal translocations by definition can only occur when there are two DNA double-strand breaks (DSBs) on distinct chromosomes that are repaired heterologously. Thus, chromosomal translocations are by their very nature problems of DNA DSB repair. Such DNA DSBs can be from internal or external sources. Internal sources of DNA DSBs that can lead to translocations can occur are inappropriate immune receptor gene maturation during V(D)J recombination or heavy-chain switching. Other internal DNA DSBs can come from aberrant DNA structures, or are generated at collapsed and reversed replication forks. External sources of DNA DSBs that can generate chromosomal translocations are ionizing radiation and cancer chemotherapy. There are several known nuclear and chromatin properties that enhance translocations over homologous chromosome DSB repair. The proximity of the region of the heterologous chromosomes to each other increases translocation rates. Histone methylation events at the DSB also influence translocation frequencies. There are four DNA DSB repair pathways, but it appears that only one, alternative non-homologous end-joining (a-NHEJ) can mediate chromosomal translocations. The rate-limiting, initial step of a-NHEJ is the binding of poly-adenosine diphosphate ribose polymerase 1 (PARP1) to the DSB. In our investigation of methods for preventing oncogenic translocations, we discovered that PARP1 was required for translocations. Significantly, the clinically approved PARP1 inhibitors can block the formation of chromosomal translocations, raising the possibility for the first time that secondary oncogenic translocations can be reduced in high risk patients.

AB - Approximately half of all cancers harbor chromosomal translocations that can either contribute to their origin or govern their subsequent behavior. Chromosomal translocations by definition can only occur when there are two DNA double-strand breaks (DSBs) on distinct chromosomes that are repaired heterologously. Thus, chromosomal translocations are by their very nature problems of DNA DSB repair. Such DNA DSBs can be from internal or external sources. Internal sources of DNA DSBs that can lead to translocations can occur are inappropriate immune receptor gene maturation during V(D)J recombination or heavy-chain switching. Other internal DNA DSBs can come from aberrant DNA structures, or are generated at collapsed and reversed replication forks. External sources of DNA DSBs that can generate chromosomal translocations are ionizing radiation and cancer chemotherapy. There are several known nuclear and chromatin properties that enhance translocations over homologous chromosome DSB repair. The proximity of the region of the heterologous chromosomes to each other increases translocation rates. Histone methylation events at the DSB also influence translocation frequencies. There are four DNA DSB repair pathways, but it appears that only one, alternative non-homologous end-joining (a-NHEJ) can mediate chromosomal translocations. The rate-limiting, initial step of a-NHEJ is the binding of poly-adenosine diphosphate ribose polymerase 1 (PARP1) to the DSB. In our investigation of methods for preventing oncogenic translocations, we discovered that PARP1 was required for translocations. Significantly, the clinically approved PARP1 inhibitors can block the formation of chromosomal translocations, raising the possibility for the first time that secondary oncogenic translocations can be reduced in high risk patients.

UR - http://www.scopus.com/inward/record.url?scp=85025595140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025595140&partnerID=8YFLogxK

M3 - Article

VL - 127

SP - 176

EP - 195

JO - Transactions of the American Clinical and Climatological Association

JF - Transactions of the American Clinical and Climatological Association

SN - 0065-7778

ER -